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Introduction: Although smoking causes adverse outcomes in cancer 
patients, most oncology providers do not regularly provide smoking 
cessation support. The purpose of this study was to identify key areas 
that can be targeted to improve delivery of evidence-based cessation 
support for cancer patients.
Methods: In 2012, the International Association for the Study of 
Lung Cancer surveyed members asking about tobacco assessment 
and cessation practices for cancer patients. Responses from 1153 
physician level oncology providers were analyzed to evaluate the 
effects of respondent demographics, tobacco use perceptions, and 
perceived barriers to providing cessation support on practice patterns.
Results: Respondents from the United States generally reported 
higher rates of asking about tobacco use, advising patients to quit, 
and assisting patients in quitting smoking. Work setting, time since 
completing a terminal degree, percent of time devoted to clinical 
care, and history of tobacco use were generally associated with ask-
ing about tobacco use and advising patients to quit, but not associated 
with discussing medications or actively treating patients. The domi-
nant multivariate barriers to providing cessation support were a lack 
of clinician education or experience and lack of available resources 
to refer patients for smoking cessation support. Patient resistance to 
treatment, inability for patients to quit smoking, or feeling that smok-
ing was not an important part of cancer outcome or cancer care had 
less meaningful associations with providing support.
Conclusions: Improving clinician education and developing dedi-
cated resources to provide cessation support were identiﬁed as 
ideal targets to address for improving cessation support for cancer 
patients.
Key Words: Smoking, Tobacco, Cancer, Oncologists, Lung, 
Thoracic, Cessation.
(J Thorac Oncol. 2015;10: 1532–1537)
Tobacco causes many cancers, and evidence now demon-strates that continued smoking by cancer patients after 
diagnosis causes adverse cancer treatment outcomes.1 The 
2014 Surgeon General’s Report concludes that smoking by 
cancer patients and survivors increases overall mortality, 
cancer-speciﬁc mortality, and risk of developing a second pri-
mary cancer with further associations with increased cancer 
recurrence and cancer treatment toxicity.1 As a result, address-
ing smoking by cancer patients is increasingly recognized as 
an essential part of cancer care.
Leading cancer organizations including the American 
Society for Clinical Oncology (ASCO), the American 
Association for Cancer Research, the Oncology Nursing 
Society, the International Association for the Study of Lung 
Cancer (IASLC), and the National Comprehensive Cancer 
Network (NCCN) have advocated for providing cessation sup-
port to cancer patients.2–6 Recent guidelines from the NCCN 
provide guidance for smoking cessation in cancer patients.6 
However, repeated surveys of oncology providers demonstrate 
that while most clinicians ask their patients about tobacco use 
and advise patients to stop smoking, few discuss medications 
or actively provide tobacco cessation support.7,8 Methods that 
have been used to try and increase the delivery of tobacco ces-
sation support have included disseminating self-help materi-
als, training healthcare providers to assess and treat tobacco 
addiction, and developing systems to identify tobacco use and 
refer patients to dedicated trained tobacco cessation counsel-
ors.9–11 Unfortunately, these resources and interventions do 
not seem to have improved clinical interventions for cancer 
patients who smoke. The consistent delivery of cessation sup-
port remains the exception rather than the rule and there are 
limited data to suggest the optimal approach to increase ces-
sation support activities by oncology providers.
In 2012, the IASLC administered a survey to members 
asking about tobacco assessment and cessation practices.7 
Included were questions asking about perceived barriers to 
providing cessation support. The purpose of this study is to 
examine which demographic characteristics and perceived 
barriers were associated with physician reported differences 
in providing cessation support.
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MATERIALS AND METHODS
The study was approved by the Institutional Review 
Board at Roswell Park Cancer Institute (Buffalo, NY). The 
survey methods have been previously described.7 In brief, a 
questionnaire was developed and administered on-line to 
IASLC members, asking about tobacco assessment and ces-
sation practices, perceptions of tobacco use in cancer patients, 
and barriers to implementing tobacco cessation support. Of 
3719 IASLC members invited to participate, 1507 (40.5%) 
completed the survey.7 Among respondents, 87% were medical 
doctors, 29% were from Europe, 23% were from the United 
States, and 12% were from Japan. Among medical doctors, 
most (70%) practiced in a university or academic setting, 
73% reported more than 10 years of practice experience, and 
77% spent at least 50% of their time in clinical practice. This 
analysis was restricted to medical doctors (or equivalent) who 
responded to the survey, reported treating cancer patients, and 
reported medical oncology, pulmonary medicine, surgery, or 
radiation oncology as their primary practice. Respondents who 
were not medical doctors or who reported primary practice in 
other medical specialties (such as pathology or radiology) were 
excluded from this analysis because these respondents were 
felt to have less direct contact with patients where tobacco 
assessments and cessation support could be provided. Of 
1304 respondents reported having a medical doctorate, 1153 
(88.5%) reported primary practice in radiation oncology, medi-
cal oncology, surgery, or pulmonary medicine. All subsequent 
analyses were performed in these 1153 respondents.
Comparative analyses were performed to evaluate the 
association between demographic factors (country of prac-
tice, work setting, years passed since completion of termi-
nal degree, time spent in clinical practice, and tobacco use) 
and tobacco assessment practices (asking about tobacco use, 
asking if patients will quit, advising patients to stop tobacco 
use, discussing medications, and actively treating patients for 
tobacco use). Further analyses were performed to evaluate the 
association between perceived barriers to providing cessations 
support to identify potential barriers that may be effective tar-
gets for intervention to improve tobacco cessation activities 
provided by oncology providers.
All the analyses were done using SAS 9.4. To evaluate 
the effects of covariates on practice patterns, a logistic regres-
sion model was ﬁtted. For each question, the probability of 
a positive answer (always/most of the time) was considered. 
Odds ratio estimates with 95% Wald conﬁdence interval esti-
mates were obtained comparing odds of a positive answer for 
each level of the covariates. The effect of perceptions was 
evaluated adjusting for the demographics that were already 
shown to be signiﬁcant.
RESULTS
Demographic Characteristics, Practice 
Patterns, and Perceived Barriers 
by Physician Respondents
The characteristics of 1153 physician respondents are 
shown in Table 1. Most respondents reported practice in 
Europe (29.7%), the United States (22.2%), or Japan (12.2%) 
with fewer than 10% of respondents from any other country 
or continent. Most practiced in a university or academic set-
ting (70.9%), most were in practice for more than 10 years 
(72.2%), and most spent more than 50% of their time in clini-
cal practice (80.3%). Although 71.1% reported never having 
used tobacco, 4.8% reported current tobacco use.
Respondents were analyzed according to whether they 
reported “always” or “most of the time” providing a patient activ-
ity and according to whether they “strongly agreed” or “agreed” 
with potential barriers (Tables 2 and 3). In the 1153 physician 
respondents, nearly all (97.2%) asked about tobacco use, 85.3% 
of respondents asked patients if they would stop using tobacco, 
and 87.0% advised patients who smoked to stop. However, only 
44.0% discussed medication options and 42.2% actively treated 
or referred patients for cessation treatment. More than 90% of 
respondents believed that smoking impacted cancer treatment 
outcomes and that tobacco cessation should be a standard part 
of cancer treatment. However, only 34.5% reported having ade-
quate training in tobacco cessation interventions.
Correlates of Tobacco Assessment 
and Cessation Practices
The associations of geographic location, work setting, 
years passed since completion of a terminal degree, percent-
age of time providing care for cancer patients, and tobacco use 
TABLE 1. Demographic and Practice Characteristics of 
Respondents (n = 1153)
Demographic Variable Number (%)
Country/continent Europe 343 (29.7)
United States 256 (22.2)
Japan 141 (12.2)
Asia 100 (8.7)
South America 75 (6.5)
Australia 61 (5.3)
China 49 (4.2)
Canada 49 (4.2)
United Kingdom 43 (3.7)
Other 36 (3.1)
Work setting University or academic 818 (70.9)
Hospital based 
nonacademic
274 (23.8)
Other 61 (5.3)
Years passed since completion  
of terminal degree
<5 yr 110 (9.5)
6–10 yr 210 (23.8)
11–20 yr 374 (32.4)
20+ yr 459 (39.8)
Time devoted to patient care 1–24% 56 (4.9)
25–49% 171 (14.8)
50–74% 508 (44.1)
75–100% 418 (36.3)
Tobacco use history Never 820 (71.1)
Former 272 (23.6)
Current 55 (4.8)
Other 6 (0.5)
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history with tobacco assessment and cessation practices at ini-
tial patient encounter are shown in Table 4. In general, practice 
in the United States was associated with a higher likelihood 
of asking patients about tobacco use and addressing tobacco 
use overall. Additional positive associations for asking about 
tobacco use included practice at a university or academic cen-
ter, a longer time in practice, devoting more time to patient 
care, and not reporting a current smoking habit. Similar pat-
terns were noted for asking patients if they will quit smok-
ing and advising patients who smoke to stop. Notably, work 
setting, time in practice, percent of time devoted to patient 
care, and smoking habit were not signiﬁcantly associated with 
discussing medications or actively treating patients.
Respondents were asked about their opinions regard-
ing tobacco use in cancer patients and were asked to rate sev-
eral potential barriers to assessing tobacco use and providing 
tobacco cessation support. The associations of these barrier per-
ceptions with tobacco cessation action, adjusted for the demo-
graphic factors described in Table 4, are described in Table 5.
Several provider level questions were asked about 
tobacco assessment and cessation practices. Believing that 
smoking affects treatment outcome was positively associated 
with asking patients if they smoke. However, believing smok-
ing cessation should be a standard of care for cancer patients 
positively predicted for asking patients to quit, advising peo-
ple to quit, and actively treating patients. Patient resistance to 
treatment was not associated with any tobacco assessment or 
cessation practice. However, a perception that smoking cessa-
tion was a waste of time was negatively associated with dis-
cussing medications and actively treating patients.
A few questions were asked regarding education and 
experience in providing cessation support. A clinician’s percep-
tion that he or she has adequate training was positively associ-
ated with asking patients if they will quit, discussing medication 
options, and actively treating patients. In contrast, a lack of 
training was negatively associated with discussing medications. 
Responding that clinicians need more cessation support train-
ing was positively associated with asking patients if they will 
quit smoking and for discussing medication options.
Several systems level questions were also asked. A per-
ceived lack of time for counseling was not associated with 
asking about tobacco use, asking patients to quit, or advis-
ing patients to quit. However, a lack of time was negatively 
associated with discussing medications and actively treating 
patients. Reimbursement was not associated with any tobacco 
assessment or cessation practice. A lack of available resources 
was negatively associated with actively treating patients but 
not with any other tobacco assessment or cessation practice.
DISCUSSION
Although the ﬁrst step in addressing tobacco use by 
cancer patients is asking about tobacco, effectively addressing 
tobacco use requires discussing medication options and actively 
providing tobacco cessation support. In this restricted analysis 
of 1153 medical oncologists, radiation oncologists, surgeons, 
and pulmonologists where 97.2% reported regularly asking 
about tobacco use, results show that lack of time for counseling, 
lack of cessation training or experience, and lack of tobacco 
cessation resources were the primary factors associated with 
decreased cessation support. Notably, these factors were not 
associated with tobacco assessment or advice to quit smok-
ing. Reimbursement and perceived patient resistance to treat-
ment were also not associated with decreased cessation support 
activities. Although the perception that cessation does not affect 
outcome was associated with decreased cessation support activ-
ity, more than 90% of respondents felt that current smoking 
affected cancer treatment outcome, and that cessation should be 
a standard part of cancer care. Collectively, these data suggest 
that developing dedicated cessation support resources and clini-
cian education are optimal targets to improve tobacco cessation 
activities by physicians who care for cancer patients.
TABLE 2. Practice Patterns and Perceptions of Respondents
Activity
Percent of respondents who 
reported “always” or “most of 
the time” (%)
  Ask your patients if they smoke 1121 (97.2)
  Ask patients who smoke if they  
 will quit
983 (85.3)
  Advise patients who smoke to stop 1003 (87.0)
  Discuss medication options 507 (44.0)
  Actively treat or refer patients 487 (42.2)
TABLE 3. Perceptions and Barriers to Providing Cessation Support for Cancer Patients
Perceptions and barriers Respondents who reported “strongly agree” or “agree” (%)
  Current smoking or tobacco use impacts treatment outcomes in cancer patients 1065 (92.4)
  Tobacco cessation should be a standard part of cancer treatment interventions 1042 (90.4)
  Waste of time—cessation does not affect outcomes in cancer patients 139 (12.1)
  Inability to get patients to quit tobacco use 685 (59.4)
  Patient resistance to cessation treatment 793 (68.8)
  I have had adequate training in tobacco assessment and cessation interventions 398 (34.5)
  Lack of training or experience in tobacco cessation interventions 544 (47.2)
  Clinicians need more training in tobacco assessment and cessation interventions 961 (83.3)
  Lack of time for counseling or to set up a referral 533 (46.2)
  None or limited provider reimbursement 365 (31.7)
  Lack of available resources or referrals for cessation interventions 550 (47.7)
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An interesting demographic pattern was noted in that 
practice in the United States was generally associated with 
equivalent or superior tobacco assessment and cessation prac-
tices overall (Table 4). Whereas work setting, time in practice, 
time devoted to patient care, and smoking status had associa-
tions with asking and advising, only the country/continent of 
practice was associated with discussing medications or actively 
treating patients. This infers that geographic influences may be 
primary demographic determinants in providing cessation sup-
port to cancer patients. However, there is no direct inference on 
the mechanism, such as governmental influence, available medi-
cal resources, cultural effects, or other potential geographical 
influences. Clear data have shown that geographic influences 
can signiﬁcantly change tobacco control practices.1 Although 
not asked as a part of the IASLC survey, these data suggest that 
influencing practice patterns at a governmental, geographic, and 
perhaps cultural level may signiﬁcantly influence cessation prac-
tices for cancer patients. Notably, although practice patterns may 
seem better in the United States, data suggest there are still sig-
niﬁcant gaps in providing cessation support for cancer patients 
in the United States.7–9,12 Consequently, the need to improve ces-
sation practices seems to be a global issue for cancer patients.
Providing clinician education to increase tobacco cessa-
tion support by physicians has been advocated for by several 
cancer organizations.2–6 Data from this study show that a per-
ception that smoking cessation improves clinical outcome and 
feeling adequately trained to deliver cessation support are asso-
ciated with a greater likelihood of providing cessation support 
to patients. ASCO provides well-developed cessation education 
tools designed for clinical oncologists that discuss the effects of 
smoking on cancer treatment, the need to address tobacco use, 
methods to assess tobacco use, strategies that can be used to 
help patients quit, medications used for cessation support, and 
other available on-line resources.13 Newly released smoking 
cessation guidelines from the NCCN provide further evidence-
based guidelines to improve smoking cessation effectiveness 
for cancer patients.6 Several recent reviews have discussed 
methods to address tobacco use in cancer patients.10,11,14,15 These 
approaches are based on evidence-based guidelines from the 
Public Health Service detailing the need for structured cessa-
tion support using behavioral counseling and pharmacotherapy 
TABLE 4. Effects of Country, Work Setting, Years Passed Since Terminal Degree, Percent of Time Devoted to Patient Care, and 
History of Tobacco Use on Practice Patterns in Respondents
Demographic Factor (Reference 
Category)
Ask your Patients 
if They Smoke, OR 
(95% CI)
Ask Patients Who 
Smoke if They Will  
Quit, OR (95% CI)
Advise Patients Who 
Smoke to Stop, OR 
(95% CI)
Discuss Medication 
Options, OR  
(95% CI)
Actively Treat or 
Refer Patients, OR 
(95% CI)
Country (USA)
  Australia 0.274 (0.036–2.11) 0.212 (0.101–0.446) 0.176 (0.078–0.399) 0.373 (0.210–0.664) 0.318 (0.175–0.576)
  Canada 0.157 (0.026–0.924) 0.249 (0.111–0.556) 0.133 (0.058–0.306) 0.294 (0.155–0.557) 0.134 (0.060–0.299)
  China 0.057 (0.011–0.283) 0.194 (0.087–0.432) 0.328 (0.124–0.868) 0.23 (0.118–0.449) 0.353 (0.184–0.679)
  Japan 0.308 (0.064–1.48) 0.475 (0.246–0.918) 0.381 (0.183–0.790) 0.253 (0.161–0.398) 0.246 (0.155–0.391)
  United Kingdom 0.063 (0.012–0.347) 0.153 (0.068–0.343) 0.144 (0.060–0.349) 0.227 (0.113–0.456) 0.244 (0.260–7.086)
  Africa 0.063 (0.008–0.528) 0.424 (0.114–1.57) 0.417 (0.093–1.86) 0.401 (0.156–1.034) 0.407 (0.156–1.061)
  Asia 0.510 (0.078–3.35) 0.526 (0.25–1.105) 0.395 (0.174–0.897) 0.250 (0.152–0.413) 0.359 (0.220–0.586)
  Europe 0.197 (0.048–0.813) 0.523 (0.294–0.933) 0.418 (0.217–0.805) 0.334 (0.233–0.479) 0.438 (0.307–0.623)
  North America 0.083 (0.009–0.804) 0.426 (0.087–2.10) 0.088 (0.022–0.349) 0.576 (0.170–1.953) 1.647 (0.432–6.275)
  South America 0.177 (0.032–0.996) 0.705 (0.293–1.70) 0.252 (0.108–0.587) 0.297 (0.170–0.519) 0.815 (0.470–1.414)
  Other 0.020 (0.002–0.189) 0.349 (0.044–2.73) 0.225 (0.029–1.74) 0.516 (0.106–2.506) 1.357 (0.260–7.086)
Work setting (academic/university)
  Hospital based/non-academic 0.427 (0.204–0.895) 0.792 (0.533–1.178) 0.634 (0.423–0.948) 1.107 (0.821–1.493) 1.297 (0.959–1.754)
  Other 0.131 (0.046–0.376) 0.452 (0.228–0.895) 0.743 (0.354–1.56) 1.708 (0.984–2.967) 1.699 (0.980–2.948)
Years passed since terminal degree (≤5 yr)
  6–10 yr 0.978 (0.360–2.66) 1.29 (0.694–2.41) 1.168 (0.59–2.31) 0.904 (0.56–1.461) 1.002 (0.616–1.631)
  11–20 yr 1.90 (0.716–5.03) 1.33 (0.757–2.35) 0.936 (0.507–1.73) 0.822 (0.527–1.28) 0.905 (0.577–1.42)
  20+ yr 3.412 (1.24–9.36) 1.416 (0.81–2.47) 1.149 (0.626–2.11) 0.952 (0.618–1.468) 1.322 (0.853–2.048)
Percent time devoted to patient care (≥75%)
  1–24% 0.065 (0.017–0.241) 0.511 (0.234–1.12) 0.321 (0.154–0.669) 0.819 (0.456–1.472) 0.867 (0.482–1.561)
  25–49% 0.107 (0.039–0.293) 0.369 (0.227-.601) 0.516 (0.308–0.863) 0.755 (0.514–1.11) 0.742 (0.502–1.097)
  50–74% 0.295 (0.119–0.734) 0.747 (0.502–1.11) 1.006 (0.667–1.52) 0.872 (0.66–1.51) 0.946 (0.714–1.252)
History of tobacco use (current smoker)
  Former smoker 2.154 (0.644–7.20) 2.627 (1.32–5.21) 2.158 (1.057–4.4) 1.242 (0.672–2.293) 1.137 (0.619–2.086)
  Never 2.479 (0.865–7.10) 3.021 (1.61–5.65) 2.474 (1.282–4.77) 1.322 (0.742–2.354) 1.118 (0.632–1.98)
  Other 0.003 (<0.001–0.02) 0.106 (0.025–0.454) 0.052 (0.011–0.238) 3.228 (0.843–12.35) 2.768 (0.727–10.54)
Signiﬁcant associations are shown in bold.
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to improve successful quit attempts by people who smoke.16 
In brief, clinicians should ask patients about tobacco use with 
structured assessments, identify patients who use tobacco, 
advise patients to quit smoking, provide behavioral counseling 
and medications to help patients quit smoking, and follow-up 
with repeated assessments, support, and treatment modiﬁcation 
as needed. Several on-line and intensive in-person training pro-
grams are also available to help education clinicians on speciﬁc 
treatment methods to help clinicians increase their experience 
base and ability to provide evidence-based cessation support to 
patients who use tobacco.17 Data demonstrating that perceiv-
ing smoking cessation improves outcome, feeling adequately 
trained to deliver cessation support, and advocacy for additional 
training of oncologists (Table 4) all reflect a positive potential 
effect of developing clinician education initiatives.
A complementary approach to solely educating clinicians 
is to develop dedicated tobacco cessation resources that clini-
cians can use to help patients quit using tobacco. This approach 
addresses all three signiﬁcant predictive barriers to providing 
cessation support: lack of experience, lack of time, and lack 
of resources. Several existing programs in the United States 
have had success in treating cancer patients using different 
approaches. For example, some cessation programs offer more 
intensive cessation support services including intensive assess-
ment, behavioral counseling, pharmacotherapy, biochemical 
monitoring, and treatment of psychiatric comorbidities where 
necessary.18,19 In contrast, other programs have used automated 
referrals to phone-based institutional cessation programs or 
programs that incorporated referrals to state quitlines available 
in the United States.20,21 There are several approaches to the 
development of dedicated cessation programs that include con-
sideration for methods of assessing tobacco, which healthcare 
providers will provide cessation support, what setting is avail-
able to provide cessation support, what resources are needed 
from the institution or community, and how cessation interven-
tions will be communicated back to clinicians.10,11 However, 
there is no one single solution to providing cessation support 
and not all institutions or clinical practices can provide the same 
level of dedicated cessation support for cancer patients. In con-
trast, all clinicians should ask about tobacco use, advise patients 
to quit, and provide cessation support either directly or through 
referral to an evidence-based cessation program.10,11,13–15
Importantly, a perceived inability to get patients to quit 
and patient resistance to treatment were not signiﬁcant predictors 
for discussing medications or actively treating patients (Table 5). 
These data suggest that clinicians may not change patterns of ces-
sation support based on feelings that patients cannot quit. There 
is considerable debate on the importance of readiness to quit 
in the general population that may contrast with a need to quit 
smoking to improve cancer treatment outcomes. Traditionally, 
patients who are asked about tobacco use are provided the option 
to participate in a tobacco cessation attempt, or quit attempt, if 
they report being ready to quit.12 Given the signiﬁcant adverse 
effects of tobacco on cancer treatment outcomes,1 the urgency 
to quit smoking by cancer patients may be greater because of 
the general need to start cancer treatment relatively quickly. As 
such, traditional approaches to picking a quit date several weeks 
or months in the future may have direct clinical relevance to the 
efﬁcacy and toxicity of cancer treatment. Readiness to quit is 
also directly related to whether clinicians should refer all patients 
for cessation support, or whether only patients who are ready to 
quit should be referred for cessation support. A recent discus-
sion provides a strong argument for developing “opt-out” pro-
grams for tobacco cessation where all patients who use tobacco 
TABLE 5. Multivariate Associations of Perceptions and Barriers on Practice Patterns in Respondents
Perceptions and Barriers
Ask Your Patients  
if They Smoke,  
OR (95% CI)
Ask Patients Who  
Smoke if They Will  
Quit, OR (95% CI)
Advise Patients  
Who Smoke to  
Stop, OR (95% CI)
Discuss Medication  
Options,  
OR (95% CI)
Actively Treat or  
Refer Patients,  
OR (95% CI)
Current smoking or tobacco use impacts 
treatment outcomes in cancer patients
1.79 (0.91–3.52) 1.07 (0.79–1.46) 1.21 (0.89–1.66) 1.19 (0.93–1.53) 1.16 (0.90–1.50)
Tobacco cessation should be a standard part 
of cancer treatment interventions
1.06 (0.55–2.04) 2.07 (1.56–2.75) 1.74 (1.31–2.32) 1.17 (0.92–1.49) 1.52 (1.18–1.96)
Waste of time- cessation does not affect 
outcomes in cancer patients
1.37 (0.90–2.07) 1.09 (0.89–1.33) 1.24 (1.02–1.51) 0.84 (0.73–0.96) 0.76 (0.66–0.88)
Inability to get patients to quit tobacco use 1.12 (0.71–1.77) 1.32 (1.07–1.61) 1.19 (0.97–1.47) 1.01 (0.87–1.16) 1.03 (0.89–1.19)
Patient resistance to cessation treatment 1.16 (0.75–1.82) 0.90 (0.72–1.11) 1.02 (0.82–1.27) 0.90 (0.77–1.05) 0.94 (0.81–1.11)
I have had adequate training in tobacco 
assessment and cessation interventions
1.03 (0.65–1.64) 1.40 (1.14–1.71) 1.19 (0.97–1.45) 1.39 (1.22–1.58) 1.64 (1.43–1.88)
Lack of training or experience in tobacco 
cessation interventions
1.23 (0.72–2.09) 1.01 (0.79–1.30) 1.06 (0.82–1.37) 0.70 (0.59–0.84) 0.92 (0.77–1.09)
Clinicians need more training in tobacco 
assessment and cessation interventions
0.95 (0.55–1.64) 1.35 (1.05–1.73) 1.23 (0.95–1.59) 1.33 (1.11–1.60) 1.06 (0.88–1.27)
Lack of time for counseling or to set up a 
referral
1.09 (0.68–1.76) 0.94 (0.76–1.15) 0.93 (0.75–1.15) 0.79 (0.69–0.91) 0.80 (0.69–0.93)
None or limited provider reimbursement 0.97 (0.61–1.55) 0.90 (0.73–1.11) 0.87 (0.70–1.08) 1.12 (0.97–1.30) 1.00 (0.86–1.16)
Lack of available resources or referrals for 
cessation interventions
0.93 (0.55–1.58) 0.87 (0.69–1.09) 1.10 (0.87–1.40) 0.92 (0.78–1.08) 0.70 (0.60–0.83)
Analyses are adjusted for country, work setting, years passed since terminal degree, percent of time devoted to patient care, and history of tobacco use. Signiﬁcant associations are 
shown in bold.
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are referred for cessation support and have the option of refusing 
support after being contacted by the tobacco cessation program.12 
The fundamental argument is that evidence-based cessation sup-
port will be available to a much broader audience and that most 
people who smoke are receptive to cessation support. However, 
an “opt-out” approach may offend some patients and may not 
be ready for mainstream practice.22 In the oncology setting, an 
“opt-out” cessation program in over 2700 cancer patients who 
reported tobacco use demonstrated that the overwhelming major-
ity of cancer patients contacted by the cessation program were 
receptive to intervention.20 Similar high rates of participation 
have been observed in other “opt out” approaches in head/neck 
cancer patients.23 Because smoking causes a broad spectrum of 
adverse outcomes in cancer patients, clinicians should emphasize 
the importance for all cancer patients to receive evidence-based 
cessation support, either by the clinicians themselves or through 
the use of dedicated tobacco cessation resources.
The results of the IASLC survey are remarkably similar to 
results from nearly 1200 ASCO members administered a nearly 
identical survey.8 Thus, although the original survey reliability 
was not tested before administration, results from respondents 
suggest the survey instrument yields consistent results among 
a diverse group of oncologists.7,8 Respondents also show a high 
proportion of practice in the university or academic setting. 
Thus, results may not be reflective of practice patterns in the 
community setting. Although pilot programs suggest addressing 
these issues in an academic or community setting can signiﬁ-
cantly increase cessation support for cancer patients,20,21 addi-
tional prospective work on integrating clinician education and 
dedicated resources into oncology practice are needed to deter-
mine if these will affect cessation support for cancer patients.
To optimize approaches that improve cessation support for 
cancer patients, it is important to consider the signiﬁcant factor 
and the prevalence of the factor under consideration (Tables 2, 3, 
and 5). Whereas feeling smoking affects outcome, cessation 
should be a standard of care, or feeling cessation is a waste 
of time may contribute to cessation activities, differences in 
these variables were reported by a small proportion (12-15%) 
of responding physicians (Tables 2 and 3). Although a per-
ceived inability to get patients to quit and patient resistance are 
reported by 60% to 69% of respondents, there was no signiﬁ-
cant effect on tobacco cessation practices (Table 5). However, 
the effects of training and experience, reported as important by 
35% to 83% of respondents, were signiﬁcant particularly for 
discussing medications and actively treating patients. Similarly, 
a lack of time and available resources, reported as signiﬁcant 
by 46% to 48% of respondents, were signiﬁcantly associated 
with decreases in discussing medications and actively treating 
patients. As a result, these data suggest that clinician education 
on smoking cessation and the development of dedicated cessa-
tion resources may be high-yield targets to optimally improve 
cessation support for cancer patients.
In summary, physicians report that lack of experience, 
lack of time, and lack of resources are barriers to providing 
cessation support to their cancer patients. Addressing these 
barriers by providing education to oncologists on the impor-
tance of tobacco cessation and developing dedicated tobacco 
cessation programs where they can refer patients should 
improve the delivery of tobacco cessation support to cancer 
patients and provide effective solutions for cancer patients to 
receive evidence-based clinical care.
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